Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

*Pooled data analysis from 22 studies. † Lupus in minorities: nature versus nurture [Unpublished Observ., May 2008]. Lupus occurs only in young women Lupus may occur at any age and in both ...

Systemic lupus erythematosus (SLE ... mice has shown that NPSLE-like symptoms and olfactory impairment might be induced by autoimmune mechanisms that target specific areas of the brain, but ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus medication litifilimab. In return, Royalty Pharma will receive undisclosed ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE ... If it makes it to market, the drug could provide a much-needed new treatment for SLE, a chronic ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

AstraZeneca's Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus (SLE) in the EU for more than 10 years.